These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 15314040)

  • 1. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.
    Takasuka N; Fujii H; Takahashi Y; Kasai M; Morikawa S; Itamura S; Ishii K; Sakaguchi M; Ohnishi K; Ohshima M; Hashimoto S; Odagiri T; Tashiro M; Yoshikura H; Takemori T; Tsunetsugu-Yokota Y
    Int Immunol; 2004 Oct; 16(10):1423-30. PubMed ID: 15314040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.
    Tsunetsugu-Yokota Y; Ato M; Takahashi Y; Hashimoto S; Kaji T; Kuraoka M; Yamamoto K; Mitsuki YY; Yamamoto T; Oshima M; Ohnishi K; Takemori T
    Jpn J Infect Dis; 2007 May; 60(2-3):106-12. PubMed ID: 17515642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
    Iwata-Yoshikawa N; Uda A; Suzuki T; Tsunetsugu-Yokota Y; Sato Y; Morikawa S; Tashiro M; Sata T; Hasegawa H; Nagata N
    J Virol; 2014 Aug; 88(15):8597-614. PubMed ID: 24850731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
    Gai WW; Zhang Y; Zhou DH; Chen YQ; Yang JY; Yan HM
    Virol Sin; 2011 Apr; 26(2):81-94. PubMed ID: 21468931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
    Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
    J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of two hemagglutinating encephalomyelitis coronavirus vaccine candidates in mice.
    Chen K; Zhao K; He W; Gao W; Zhao C; Wang L; Pan W; Song D; Wang C; Gao F
    Clin Vaccine Immunol; 2012 Jul; 19(7):1102-9. PubMed ID: 22518008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
    Roberts A; Lamirande EW; Vogel L; Baras B; Goossens G; Knott I; Chen J; Ward JM; Vassilev V; Subbarao K
    Viral Immunol; 2010 Oct; 23(5):509-19. PubMed ID: 20883165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.
    Gai W; Zou W; Lei L; Luo J; Tu H; Zhang Y; Wang K; Tien P; Yan H
    Viral Immunol; 2008 Mar; 21(1):27-37. PubMed ID: 18355120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
    Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
    Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
    Zhang CH; Guo ZM; Zheng HY; Lu JH; Wang YF; Yan XG; Zhao Y; DU XW; Zhang X; Fang L; Ling WH; Qi SY; Yu XB; Zhong NS
    Chin Med J (Engl); 2004 Nov; 117(11):1625-9. PubMed ID: 15569476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.
    Qiu X; Hong C; Li Y; Bao W; Gao XM
    Microbiol Immunol; 2012 Aug; 56(8):554-61. PubMed ID: 22530918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.
    Qin E; Shi H; Tang L; Wang C; Chang G; Ding Z; Zhao K; Wang J; Chen Z; Yu M; Si B; Liu J; Wu D; Cheng X; Yang B; Peng W; Meng Q; Liu B; Han W; Yin X; Duan H; Zhan D; Tian L; Li S; Wu J; Tan G; Li Y; Li Y; Liu Y; Liu H; Lv F; Zhang Y; Kong X; Fan B; Jiang T; Xu S; Wang X; Li C; Wu X; Deng Y; Zhao M; Zhu Q
    Vaccine; 2006 Feb; 24(7):1028-34. PubMed ID: 16388880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of SARS virus vaccines.
    Zheng BJ; Du LY; Zhao GY; Lin YP; Sui HY; Chan C; Ma S; Guan Y; Yuen KY
    Hong Kong Med J; 2008 Aug; 14 Suppl 4():39-43. PubMed ID: 18708674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine.
    Zakhartchouk AN; Sharon C; Satkunarajah M; Auperin T; Viswanathan S; Mutwiri G; Petric M; See RH; Brunham RC; Finlay BB; Cameron C; Kelvin DJ; Cochrane A; Rini JM; Babiuk LA
    Vaccine; 2007 Jan; 25(1):136-43. PubMed ID: 16919855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen.
    Tsunetsugu-Yokota Y
    Methods Mol Biol; 2008; 454():119-26. PubMed ID: 19057880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.
    Chen WH; Du L; Chag SM; Ma C; Tricoche N; Tao X; Seid CA; Hudspeth EM; Lustigman S; Tseng CT; Bottazzi ME; Hotez PJ; Zhan B; Jiang S
    Hum Vaccin Immunother; 2014; 10(3):648-58. PubMed ID: 24355931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.